Phreesia (NYSE:PHR) Research Coverage Started at Barclays

Barclays initiated coverage on shares of Phreesia (NYSE:PHR) in a research note issued to investors on Monday morning, MarketBeat reports. The brokerage issued an overweight rating and a $26.00 target price on the stock.

A number of other equities research analysts have also recently weighed in on PHR. KeyCorp reduced their price objective on Phreesia from $35.00 to $32.00 and set an “overweight” rating for the company in a research note on Wednesday, October 8th. Mizuho began coverage on shares of Phreesia in a report on Wednesday, August 27th. They issued an “outperform” rating and a $36.00 target price on the stock. BMO Capital Markets initiated coverage on shares of Phreesia in a research report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price target for the company. Stephens reiterated an “overweight” rating and set a $32.00 price target on shares of Phreesia in a research note on Wednesday, September 3rd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Phreesia from $32.00 to $29.00 and set an “overweight” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Phreesia presently has a consensus rating of “Moderate Buy” and an average price target of $31.13.

Phreesia Stock Performance

NYSE PHR opened at $15.82 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12. Phreesia has a 1 year low of $15.41 and a 1 year high of $32.76. The company has a market capitalization of $947.48 million, a PE ratio of -158.13 and a beta of 0.64. The company has a fifty day moving average of $21.73 and a two-hundred day moving average of $25.12.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. The business had revenue of $120.33 million for the quarter, compared to analysts’ expectations of $119.98 million. Phreesia had a negative return on equity of 1.36% and a negative net margin of 1.16%.The business’s revenue was up 12.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.25) earnings per share. As a group, analysts expect that Phreesia will post -1.1 earnings per share for the current year.

Insider Activity at Phreesia

In other news, CFO Balaji Gandhi sold 4,183 shares of the business’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total transaction of $97,380.24. Following the transaction, the chief financial officer directly owned 99,125 shares in the company, valued at $2,307,630. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Evan Roberts sold 3,761 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $87,556.08. Following the transaction, the insider directly owned 726,837 shares of the company’s stock, valued at $16,920,765.36. This represents a 0.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 26,174 shares of company stock worth $603,835 in the last 90 days. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Phreesia

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Phreesia by 8.3% during the third quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock worth $134,177,000 after buying an additional 437,462 shares in the last quarter. Greenhouse Funds LLLP increased its holdings in Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after buying an additional 557,265 shares in the last quarter. Champlain Investment Partners LLC lifted its position in shares of Phreesia by 20.0% during the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company’s stock valued at $75,312,000 after acquiring an additional 490,340 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Phreesia by 108.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock worth $67,606,000 after acquiring an additional 1,377,904 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Phreesia by 1.9% during the 3rd quarter. Franklin Resources Inc. now owns 1,553,192 shares of the company’s stock worth $36,531,000 after acquiring an additional 28,941 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.